HSCS insider transaction filings
HeartSciences Inc. — 22 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-09. Screen HSCS transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Simpson Andrew — See Remarks, Director | 1 | — | — | 1 |
| Watson Danielle — See Remarks | 1 | — | — | 1 |
Recent Form 4 filings — HeartSciences Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-09 | 4 | Watson Danielle — See Remarks | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Simpson Andrew — See Remarks, Director | Grant/award (A): 425,000 | EDGAR |
| 2026-01-12 | 4 | Wells David R. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Bent Bruce — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Szymczak Brian — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Watson Danielle — See Remarks | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | HILZ MARK T — See Remarks | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-11-28 | 4 | Simpson Andrew — See Remarks, Director | Grant/award (A): 70,000 | EDGAR |
| 2025-07-30 | 4 | HILZ MARK T — COO, Secretary and Director, Director | Sale (S): 4,416 @ $3.54 | EDGAR |
| 2025-07-14 | 4 | Bent Bruce — Director | Grant/award (A): 25,000 (derivative) | EDGAR |
| 2025-07-11 | 4 | Szymczak Brian — Director | Grant/award (A): 25,000 (derivative) | EDGAR |
| 2025-07-11 | 4 | Simpson Andrew — See Remarks, Director | Grant/award (A): 275,000 (derivative) · Grant/award (A): 68,750 (derivative) @ $0 | EDGAR |
| 2025-07-11 | 4 | Wells David R. — Director | Grant/award (A): 25,000 (derivative) | EDGAR |
| 2025-07-11 | 4 | Watson Danielle — See Remarks | Grant/award (A): 25,000 (derivative) | EDGAR |
| 2025-07-11 | 4 | HILZ MARK T — See Remarks, Director | Grant/award (A): 225,000 (derivative) · Grant/award (A): 56,250 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Bent Bruce — Director | Grant/award (A): 6,000 (derivative) | EDGAR |
| 2025-01-21 | 4 | Wells David R. — Director | Grant/award (A): 6,000 (derivative) | EDGAR |
| 2025-01-21 | 4 | Watson Danielle — See Remarks | Grant/award (A): 9,000 (derivative) | EDGAR |
| 2025-01-21 | 4 | Szymczak Brian — Director | Grant/award (A): 6,000 (derivative) | EDGAR |
| 2025-01-21 | 4 | Simpson Andrew — See Remarks, Director | Grant/award (A): 45,000 (derivative) | EDGAR |
| 2025-01-21 | 4 | HILZ MARK T — See Remarks, Director | Grant/award (A): 45,000 (derivative) | EDGAR |
| 2024-08-14 | 4 | Simpson Andrew — See Remarks, Director | Other (J): 17 | EDGAR |
Recent 8-K events — HeartSciences Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-19 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-19 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HSCS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →